S100A1 and PYGM

Data Source:
BioGRID (pull down)
HPRD (in vivo, in vitro)

		S100A1	PYGM
Description		S100 calcium binding protein A1	glycogen phosphorylase, muscle associated
Image
GO Annotations	Cellular Component	Extracellular Region Nucleus Nucleoplasm Cytoplasm Golgi Apparatus Cytosol Sarcoplasmic Reticulum Protein-containing Complex	Cytoplasm Cytosol Extracellular Exosome
	Molecular Function	Calcium Ion Binding Protein Binding Identical Protein Binding Protein Homodimerization Activity S100 Protein Binding Calcium-dependent Protein Binding ATPase Binding	Nucleotide Binding Protein Binding Glycogen Phosphorylase Activity Pyridoxal Phosphate Binding Linear Malto-oligosaccharide Phosphorylase Activity SHG Alpha-glucan Phosphorylase Activity
	Biological Process	Toll-like Receptor Signaling Pathway Regulation Of Heart Contraction Substantia Nigra Development Intracellular Signal Transduction Positive Regulation Of Nitric-oxide Synthase Activity Positive Regulation Of Sprouting Angiogenesis	Glycogen Metabolic Process Glycogen Catabolic Process
Pathways		Regulation of TLR by endogenous ligand	Glycogen breakdown (glycogenolysis) Glycogen breakdown (glycogenolysis)
Drugs		Olopatadine	Pyridoxal phosphate Beta-D-Glucopyranose Spirohydantoin (5S,7R,8S,9S,10R)-3-Amino-8,9,10-trihydroxy-7-(hydroxymethyl)-6-oxa-1,3-diazaspiro[4.5]decane-2,4-dione alpha-D-glucose 6-phosphate N-beta-D-glucopyranosylacetamide Monofluorophosphate ion Beta-D-Glucose 3,8,9,10-tetrahydroxy-7-hydroxymethyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Nojirimycine Tetrazole Indirubin-5-sulphonate 2-Deoxy-Glucose-6-Phosphate C-(1-hydrogyl-beta-D-glucopyranosyl) formamide alpha-D-glucopyranosyl-2-carboxylic acid amide alpha-D-glucose-1-phosphate 8,9,10-Trihydroxy-7-hydroxymethyl-2-thioxo-6-oxa-1,3-diaza-spiro[4.5]decan-4-one 4-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,2,3-Benzimidazole N-acetyl-N'-beta-D-glucopyranosyl urea 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Benzothiazole C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide 2-(Beta-D-Glucopyranosyl)-5-Methyl-1,3,4-Oxadiazole CP-320626 (3,4,5-Trihydroxy-6-Hydroxymethyl-Tetrahydro-Pyran-2-Yl)-Phosphoramidic Acid Dimethyl Ester 8,9,10-trihydroxy-7-hydroxymethyl-3-methyl-6-oxa-1,3-diaza-spiro[4.5]decane-2,4-dione Alvocidib 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose N-[(5S,7R,8S,9S,10R)-8,9,10-Trihydroxy-7-(hydroxymethyl)-2,4-dioxo-6-oxa-1,3-diazaspiro[4.5]dec-3-yl]acetamide 1-Deoxy-1-methoxycarbamido-beta-D-gluco-2-heptulopyranosonamide 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid 2,3-Dicarboxy-4-(2-Chloro-Phenyl)-1-Ethyl-5-Isopropoxycarbonyl-6-Methyl-Pyridinium N(6)-(pyridoxal phosphate)-L-lysine Heptulose-2-Phosphate N-(Benzoylcarbamoyl)-beta-D-glucopyranosylamine Dexfosfoserine 1-Deoxy-1-acetylamino-beta-D-gluco-2-heptulopyranosonamide Inosinic Acid 7-{2,6-DICHLORO-4-[3-(2-CHLORO-BENZOYL)-UREIDO]-PHENOXY}-HEPTANOIC ACID 4-{3-CHLORO-4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-PHENOXY}-BUTYRIC ACID 4-{4-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2,3-DIMETHYL-PHENOXY}-BUTYRIC ACID 5-{3-[3-(2,4-DICHLORO-BENZOYL)-UREIDO]-2-METHYL-PHENOXY}-PENTANOIC ACID 2-CHLORO-N-[(1R,2R)-1-HYDROXY-2,3-DIHYDRO-1H-INDEN-2-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE 2-CHLORO-N-[(3R)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (S)-2-CHLORO-N-(1-(2-(2-HYDROXYETHYLAMINO)-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL)-6H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (2S)-N-[(3S)-1-(2-AMINO-2-OXOETHYL)-2-OXO-1,2,3,4-TETRAHYDROQUINOLIN-3-YL]-2-CHLORO-2H-THIENO[2,3-B]PYRROLE-5-CARBOXAMIDE (3R,4R,5R)-5-(HYDROXYMETHYL)-1-(3-PHENYLPROPYL)PIPERIDINE-3,4-DIOL ({[(3E)-2'-Oxo-2',7'-dihydro-2,3'-biindol-3(7H)-ylidene]amino}oxy)acetic acid (5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-phenyl-1,6-dioxa-2-azaspiro[4.5]dec-2-ene-8,9,10-triol 2-DEOXY-3,4-BIS-O-[3-(4-HYDROXYPHENYL)PROPANOYL]-L-THREO-PENTARIC ACID (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(2-naphthyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol (3S,5R,7R,8S,9S,10R)-7-(hydroxymethyl)-3-(4-methylphenyl)-1,6-dioxa-2-azaspiro[4.5]decane-8,9,10-triol
Diseases			Glycogen storage diseases (GSD), including: von Gierke disease (GSD type Ia); Pompe disease (GSD type II); Cori disease, Forbe disease (GSD type III); Andersen disease (GSD type IV); McArdle disease (GSD type V); Hers disease (GSD type VI); Tarui disease (GSD type VII); Phosphorylase kinase deficiency (GSD type IX); Fanconi-Bickel syndrome (GSD type XI); Glycogen synthase deficiency (GSD type 0)
GWAS			Urate levels ( 21768215)
Interacting Genes		30 interacting genes: ACTA1 AGER ANXA6 ATP2A2 BEX3 BIK CACYBP CAPZA1 CEP20 DES FKBP4 GFAP GJA1 MDM2 NIF3L1 PGM1 PLB1 PLEKHF2 PLN PPID PYGM REL RYR1 S100A2 S100A3 S100A4 S100B S100P S100Z SYN1	29 interacting genes: AGTPBP1 ARID1B CDC42BPB CLASP2 DNM2 FAM110A IGBP1 INTS4 LMNA NIPSNAP2 NTAQ1 PDE4DIP POMP PPP1CA PPP1R3B PPP2CA PRKAB2 PYGB PYGL S100A1 SGCG SRP72 TOP1 TRAPPC2 TRIM54 TRIM55 TRIM63 TTN WWP1
Entrez ID		6271	5837
HPRD ID		01489	01986
Ensembl ID		ENSG00000160678	ENSG00000068976
Uniprot IDs		A0A0S2Z4H2 P23297	P11217
PDB IDs		2L0P 2LHL 2LLS 2LLT 2LLU 2LP2 2LP3 2LUX 2M3W 5K89	1Z8D
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?